Covering obesity drugs could cost Medicare $35B by 2034, CBO says

While Medicare doesn’t cur­rent­ly cov­er an­ti-obe­si­ty drugs, a new re­port from the Con­gres­sion­al Bud­get Of­fice es­ti­mates that cov­er­age could cost Medicare $35 bil­lion from 2026 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.